Literature DB >> 28755708

Immunotherapy: Who Is Eligible?

Daniel Wang1, Jill Gilbert1, Young J Kim2.   

Abstract

Recurrent and/or metastatic head and neck cancer portends a poor prognosis with traditional treatments, but current immunotherapy with immune checkpoint inhibitors has the potential to improve these clinical outcomes. This review focuses on the major breakthroughs that have led to the current understanding of immunotherapy in head and neck cancer as well as the future direction of the field. Ultimately, this understanding will guide clinicians on the selection of patients with head and neck cancer and practical considerations before starting immunotherapy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Checkpoint inhibitors; Immunotherapy; Nivolumab; PD-1/PD-L1 blocking antibodies; Pembrolizumab; Recurrent metastatic head & neck carcinoma

Mesh：

Substances：

Year:  2017        PMID： 28755708      PMCID： PMC6282181          DOI： 10.1016/j.otc.2017.04.006

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN： 0030-6665            Impact factor:   3.346


  38 in total

1.  CIS-Dichlorodiammineplatinum(II) in the treatment of epidermoid carcinoma of the head and neck.

Authors:  R E Wittes; E Cvitkovic; J Shah; F P Gerold; E W Strong
Journal:  Cancer Treat Rep       Date:  1977 May-Jun

2.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

Authors:  Tanguy Y Seiwert; Barbara Burtness; Ranee Mehra; Jared Weiss; Raanan Berger; Joseph Paul Eder; Karl Heath; Terrill McClanahan; Jared Lunceford; Christine Gause; Jonathan D Cheng; Laura Q Chow
Journal:  Lancet Oncol       Date:  2016-05-27       Impact factor: 41.316

3.  Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

Authors:  Jean-Pascal H Machiels; Robert I Haddad; Jérôme Fayette; Lisa F Licitra; Makoto Tahara; Jan B Vermorken; Paul M Clement; Thomas Gauler; Didier Cupissol; Juan José Grau; Joël Guigay; Francesco Caponigro; Gilberto de Castro; Luciano de Souza Viana; Ulrich Keilholz; Joseph M Del Campo; Xiuyu Julie Cong; Eva Ehrnrooth; Ezra E W Cohen
Journal:  Lancet Oncol       Date:  2015-04-16       Impact factor: 41.316

4.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

Authors:  A A Forastiere; B Metch; D E Schuller; J F Ensley; L F Hutchins; P Triozzi; J A Kish; S McClure; E VonFeldt; S K Williamson
Journal:  J Clin Oncol       Date:  1992-08       Impact factor: 44.544

5.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

6.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

Authors:  Scott E Strome; Haidong Dong; Hideto Tamura; Stephen G Voss; Dallas B Flies; Koji Tamada; Diva Salomao; John Cheville; Fumiya Hirano; Wei Lin; Jan L Kasperbauer; Karla V Ballman; Lieping Chen
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

7.  A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.

Authors:  C Jacobs; G Lyman; E Velez-García; K S Sridhar; W Knight; H Hochster; L T Goodnough; J E Mortimer; L H Einhorn; L Schacter
Journal:  J Clin Oncol       Date:  1992-02       Impact factor: 44.544

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

10.  Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.

Authors:  Bridgette A Kanz; Megan H Pollack; Romany Johnpulle; Igor Puzanov; Leora Horn; Alicia Morgans; Jeffrey A Sosman; Suthee Rapisuwon; R Martin Conry; Zeynep Eroglu; Douglas B Johnson
Journal:  J Immunother Cancer       Date:  2016-10-18       Impact factor: 13.751
View more
  1 in total

Review 1.  Radiotherapy Controversies and Prospective in Head and Neck Cancer: A Literature-Based Critical Review.

Authors:  Francesca De Felice; Antonella Polimeni; Valentino Valentini; Orlando Brugnoletti; Andrea Cassoni; Antonio Greco; Marco de Vincentiis; Vincenzo Tombolini
Journal:  Neoplasia       Date:  2018-02-12       Impact factor: 5.715
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.